| Sept, 11th 2007 |
Board of Directors: Olivier Chesnoy (MD) is appointed as Chief Executing Officer and Chairman of the Board of Theraptosis |
| Sept, 1st 2007 |
Theraptosis is nominated in the "Entreprises d'Avenir" category for the region Ile-de-France in the "Ernst & Young / L'Entreprise" entrepreneurial contest |
| Feb, 1st 2007 |
Theraptosis R&D activities move to the Biocitech Park at Romainville (Paris North), France
|
| Dec 2006 |
Second Institutional Round of Funding:
8.4 million euro
Introduction of Auriga Partners as new investor.
Co-investors: Blue Medical, Seventure, Edmond de Rothschild (EdRIP), CDC entreprises (FCJE) |
| Oct 2006 |
Theraptosis obtains Orphan Drug Status by EU:
For a new drug candidate on development for the treatment of neonatal brain damage |
| May 2006 |
ANVAR's "Aide à l'innovation":
Funding obtained: 1.2 million euro
Second payment: 400 000 euro |
| November 2005
|
Blue Medical Invests in Theraptosis
and joins the historical
consortium (EdRIP, SPEF, CDC) |
| November 2005
|
Appointment of Antoine Ferry and Bernard Majoie as Chairman and Vice-Chairman of the Supervisory Board of Theraptosis, respectively |
| February 2005
|
Jean-François Boussard (PhD, CFO) is introduced in Board of Directors
|
| January 2005
|
Theraptosis
reinforces its Supervisory Board:
Introduction of 3 new members: Bernard Majoie, Antoine Ferry &
Cornelis Lucas |
| November 2004 |
BIORIF 2004 awards:
Etienne Jacotot, Theraptosis' CSO and CEO wins the "Bio Manager Trophee" |
| July 2004 |
ANVAR's "Aide à l'innovation":
Funding obtained: 1.2 million euro
First payment: 800 000 euro |
| January 2004 |
Achievement of
2nd Milestone:
In vivo Proof of concept (animal model) |
| December 2003 |
Bio-engineering
program (Ministry of Research):
Funding obtained: 900 000 euro |
| September 2003 |
Collaboration agreement
with the Robarts Research Institute:
Canada's top independant medical research center and Theraptosis
start collaboration in order to identify new cytoprotective molecules. |
| March 2003 |
Achievement of
1st Milestone:
Finalization of new Technological Platform. |
| November
2002 |
Research
fellowships (ANVAR & CRITT):
Funding obtained: 57 000 euro |
| July
31, 2002 |
First round of funding:
Limited company with Board of Directors and Advisory Board with
a capital of 101,460 euro
First institutional round, 2.45 million euro
3 institutional investors. |
| July
2002 |
National Award for
New Companies:
Category: creation-development
Funding obtained: 350 000 euro
|
December
2001
|
Bio-engineering
program (Ministry of Research):
Funding obtained: 870 484 euro
|
| November
2001 |
Research fellowship
(ANVAR):
Funding obtained: 27 000 euro |
| September
2001 |
National Award for New Companies:
Category: new company
Funding obtained : 45 500 euro |
| July
31, 2001 |
Priming cap:
Limited company with a capital of 53 800 euro
Introduction of Pasteur Institute Foundation |
| March
27, 2001 |
Establishment:
Limited company with a capital of 40 000 euro
|
